Vol.

No.

February 13, 2026Feb 13, 2026

DOWNLOAD THE PDF

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

Cover Story

NCI

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago

Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

By Jacquelyn Cobb

When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.

Regulatory News

CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot

By Claire Marie Porter

Black History Month Cancer History Project Free

Olopade: “The genetic basis of every cancer, or everything we do, starts in Africa.”
For Black History Month, Olopade reflects on mentorship, community, and her career in cancer genetics

By Olufunmilayo I. Olopade, Robert A. Winn and Preston Willett

NCI

NCAB ad hoc group approves seven new, reissue concepts

By Sara Willa Ernst

Free Guest Editorial

Science is winning the war on cancer—CMS shouldn’t disarm

By John M. O’Brien

Clinical Trials & Tribulations

Why infection and immunity matter for Florida’s cancer patients

By Eduardo Sotomayor

Podcast

Lowy fields questions about peer review at inaugural meeting of the new NCAB ad hoc working group

Cancer Policy

Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test

FDA approves labeling changes to menopausal hormone therapy products

HHS withdraws 340B drug rebate pilot program

In Brief

David Gius named director of University of Cincinnati Cancer Center

Team USA’s Julie Letai competes in Milan Olympics speed skating event

“The Journey to End Cancer: From Cause to Cure” exhibit launches national tour, with MD Anderson as presenting sponsor

NAM New Voices Program for emerging STEM leaders announces 2026 cohort

Curebound adds five business leaders to board to accelerate cancer research

Clinical Roundup

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

Rural cancer patients do just as well as urban patients when having surgery close to home, study finds

AI tool may help personalize ovarian cancer treatment from day one

HPV cancer vaccine slows tumor growth, extends survival in animal models

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Drugs & Targets

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FDA approves companion diagnostic for pembrolizumab for ovarian cancer

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues